Divi's Laboratories' custom synthesis segment has clocked strong year-on-year growth of 19% in the financial year 2025.

MSN Pharmaceuticals, the U.S. subsidiary of global pharmaceutical leader MSN Group, is pleased to announce the launch of its ...

“Sacubitril/valsartan has been shown to significantly improve clinical outcomes and reverse myocardial remodeling among patients with heart failure with reduced ejection fraction (HFrEF).

Sacubitril/valsartan use was determined using National Drug Codes. We generated age, sex, and race–adjusted rates of sacubitril/valsartan prescribing by hospital referral region from 2016 to 2018.

Adherence to sacubitril/valsartan was relatively good, at about 86% of prescribed patients with HF, but adherence behaviors were found to vary across subgroups, according to data published in the ...

Moreover, annual income of less than $40,000 was associated with lower odds of sacubitril/valsartan adherence (proportion of days covered of more than 80%) compared with annual income of at least ...

Sacubitril/Valsartan Is Cost-effective in Low-EF Heart Failure: Analysis Pam Harrison June 27, 2016 0 ...

Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction (EF ...

Specifically, among patients with diabetes, the magnitude of effect with sacubitril/valsartan was found to be larger than in those without diabetes (+0.6 vs +0.3mL/min/1.73m 2 per year; P= 0.038).

And treatment with sacubitril/valsartan was also tied to a reduced risk for a rise in serum creatine level than enalapril or valsartan alone (RR 0.86, 95% CI 0.78-0.95, I2 = 72%, P =0.002 ...

Sacubitril/valsartan came suggestively close to showing efficacy for preventing cardiovascular death or heart failure events in patients with acute MI but no history of heart failure.

Indeed, real-world sacubitril/valsartan users often do not reach the 97/103 mg twice daily dose that proved superior to enalapril 10 mg twice daily in PARADIGM-HF. Only participants who were able ...